UNSPSC 85831011: Phototherapy, circulatory, multiple

This classification denotes the group of activities that yields a therapeutic intervention or procedure to phototherapy, circulatory, multiple. This intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 6A651ZZ

UNSPSC 85831011 Phototherapy, circulatory, multiple is a Commodity code that sees little procurement activity aligned with its nominal scope in recent state and local solicitations. The code spans specialized medical equipment and services for circulatory phototherapy applications, yet the recent opportunities block contains no solicitations for phototherapy devices or services matching this description. Instead, the tagged opportunities span clinical laboratory testing (routine and specialized diagnostics for psychiatric hospitals, veteran centers, and health departments), occupational health screening (physicals, drug testing, medical surveillance), postmortem testing, environmental lead analysis, drug screening and confirmation testing, and histology services—none of which fall within circulatory phototherapy scope. The mismatch suggests either that state and local procurement offices are tagging non-phototherapy laboratory and medical services under this code in error, or that the code sits dormant for its intended use in this jurisdiction set.

No state or local government buyer appears in the recent opportunities block with an active solicitation for phototherapy equipment or services under this code. The geographic spread of tagged opportunities spans Illinois, Texas, Kentucky, Colorado, Michigan, Oregon, Georgia, Florida, and other states, but the work being solicited—laboratory testing, occupational health services, and drug screening—does not inform pursuit of phototherapy vendors. Business development professionals evaluating this code should treat it as inactive for circulatory phototherapy procurement and verify directly with issuing bodies whether mislabeling has occurred before investing in pursuit strategy.